(CORT) Corcept Therapeutics - Ratings and Ratios

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company focused on developing therapies for severe and life-altering medical conditions. Their lead product, Korlym, is a cortisol receptor antagonist approved for treating hyperglycemia associated with Cushings syndrome in adults who are either ineligible for or have failed surgery. This drug addresses a critical need in endocrinology, particularly for patients with type 2 diabetes or glucose intolerance linked to excessive cortisol levels.

Beyond Korlym, Corcept has a robust pipeline targeting various unmet medical needs. Relacorilant, their next-generation cortisol receptor antagonist, is in Phase III trials for Cushings syndrome, offering a potentially improved safety profile. Additionally, theyre exploring its efficacy in adrenal cancer and cortisol excess in a Phase Ib trial. The company is also investigating relacorilant combined with nab-paclitaxel in a Phase III trial for platinum-resistant ovarian cancer, which could expand its oncologic applications.

Corcepts pipeline extends into neurology and hepatology. Dazucorilant is in Phase II trials for amyotrophic lateral sclerosis (ALS), aiming to slow disease progression. Miricorilant is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a condition with limited treatment options. Furthermore, theyre developing a treatment for antipsychotic-induced weight gain, currently in Phase I, addressing a significant side effect of psychiatric medications.

Founded in 1998 and headquartered in Menlo Park, California, Corcept operates with a market capitalization of approximately $7.7 billion. Their financial metrics include a trailing P/E of 58.42 and a forward P/E of 27.70, reflecting market expectations for future earnings growth. The price-to-book ratio of 11.51 indicates a premium valuation relative to book value, likely due to the potential of their pipeline and the markets confidence in their growth prospects.